A Phase 3 interventional study of insulin degludec/insulin aspart and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 50 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-03-17.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 40th largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 18th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 296 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 173rd largest by enrollment of the 430 interventional ones that give a count, is one of 23 that started in 2011, is one of 187 in phase 3, and was the 207th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan. Depending on pre-trial oral anti-diabetic drugs (OADs), subjects continued at the same dose and dosing frequency.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 296 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart · Drug: insulin glargine
Drug: insulin glargine
Drug pages: Insulin degludecStudies of Insulin degludecInsulin degludec pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Insulin AspartStudies of Insulin AspartInsulin Aspart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
Change in Glycosylated Haemoglobin (HbA1c)
Observed change from baseline in HbA1c after 26 weeks of treatment
Time frame: Week 0, Week 26
Mean Increment of 9-point Self Measured Plasma Glucose Profile (SMPG) at the Main Evening Meal
Observed mean increment of the 9-point self-measured plasma glucose profile (SMPG) at the main evening meal
Time frame: Week 26
Rate of Treatment Emergent Adverse Events (AEs)
Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
Time frame: Week 0 to Week 26 + 7 days follow up
Rate of Confirmed Hypoglycaemic Episodes
Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Week 0 to Week 26 + 7 days follow up
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m.
Time frame: Week 0 to Week 26 + 7 days follow up
Change in Body Weight
Observed change from baseline in body weight after 26 weeks of treatment
Time frame: Week 0, Week 26
The trial was conducted at 48 sites in Japan.
| Milestone | IDegAsp OD | IGlar OD |
|---|---|---|
| Started | 147 | 149 |
| Completed | 137 | 137 |
| Not completed | 10 | 12 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 3 |
| Withdrew: Withdrawal criteria | 1 | 1 |
| Withdrew: Unclassified | 8 | 7 |
Observed change from baseline in HbA1c after 26 weeks of treatment
| percentage of glycosylated haemoglobin | IDegAsp OD | IGlar OD |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -1.35 ± 0.86 | -1.22 ± 0.98 |
Observed mean increment of the 9-point self-measured plasma glucose profile (SMPG) at the main evening meal
| mmol/L | IDegAsp OD | IGlar OD |
|---|---|---|
| Mean Increment of 9-point Self Measured Plasma Glucose Profile (SMPG) at the Main Evening Meal | 1.4 ± 4.2 | 4.7 ± 3.6 |
Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
| Events/100 years of patient exposure | IDegAsp OD | IGlar OD |
|---|---|---|
| Adverse events (AEs) | 334 | 368 |
| Serious AEs | 7 | 4 |
| Severe AEs | 1 | 0 |
| Moderate AEs | 17 | 14 |
| Mild AEs | 316 | 353 |
| Fatal AEs | 0 | 0 |
Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
| Episodes/100 years of patient exposure | IDegAsp OD | IGlar OD |
|---|---|---|
| Rate of Confirmed Hypoglycaemic Episodes | 191 | 271 |
Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m.
| Episodes/100 years of patient exposure | IDegAsp OD | IGlar OD |
|---|---|---|
| Rate of Nocturnal Confirmed Hypoglycaemic Episodes | 39 | 53 |
Observed change from baseline in body weight after 26 weeks of treatment
| kg | IDegAsp OD | IGlar OD |
|---|---|---|
| Change in Body Weight | 0.7 ± 2.8 | 0.7 ± 2.2 |
Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegAsp OD | — | 5/147 (3.4%) | 37/147 (25.2%) |
| IGlar OD | — | 3/149 (2%) | 47/149 (31.5%) |
| Event | IDegAsp OD | IGlar OD |
|---|---|---|
| Cardiac failureCardiac disorders | 1/147 | 0/149 |
| Inguinal herniaGastrointestinal disorders | 1/147 | 0/149 |
| Pulmonary tuberculosisInfections and infestations | 1/147 | 0/149 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/147 | 0/149 |
| Cerebral infarctionNervous system disorders | 1/147 | 1/149 |
| Osteitis condensansMusculoskeletal and connective tissue disorders | 0/147 | 1/149 |
| DizzinessNervous system disorders | 0/147 | 1/149 |
| Event | IDegAsp OD | IGlar OD |
|---|---|---|
| NasopharyngitisInfections and infestations | 33/147 | 38/149 |
| Diabetic retinopathyEye disorders | 8/147 | 10/149 |
| Age, Continuous(years) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Mean | 60.0 ± 10.0 | 61.0 ± 9.6 | 60.5 ± 9.8 |
| Sex: Female, Male(Participants) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Female | 57 | 50 | 107 |
| Male | 90 | 99 | 189 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Mean | 8.3 ± 0.8 | 8.5 ± 0.8 | 8.4 ± 0.8 |
| Fasting plasma glucose (FPG)(mmol/L) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Mean | 9.0 ± 1.6 | 9.1 ± 1.9 | 9.0 ± 1.7 |
| Body weight(kg) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Mean | 66.2 ± 13.4 | 66.4 ± 13.3 | 66.3 ± 13.4 |
The record gives a start of Jan 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 4 years 2 months after primary completion. A results delay was requested in Jan 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart